Abstract
BackgroundSeveral drugs are capable of promoting changes in bone metabolism. The aim of this study was to evaluate the effect of long-term low-dose aspirin (LDA) therapy on implant osseointegration.MethodsMale Wistar rats were divided into 4 groups (n = 8/group) according to oral gavage solution received prior (42 days) to the implant surgery on the tibia. The control group was treated with saline solution for 7 (CG-7) and 28 (CG-28) days. The use of low-dose aspirin was performed in AG groups (6.75 mg/kg of aspirin) for 7 (AG-7) and 28 (AG-28) days. After experimental periods, histomorphometric evaluation of bone-to-implant contact (BIC) and the bone area between threads (BABT) was performed.ResultsReduced BIC values were detected in AG-7 (62.8% ± 17.1) group compared to AG-28 (91.9% ± 5.4), CG-7 (82.7% ± 15.2), and CG-28 (89.9% ± 9.7). BABT evaluation revealed lower values in AG-7 (70.9% ± 15.2) compared to AG-28 (95.4% ± 3.7) and CG-28 (87.1% ± 10.2) groups.ConclusionsThe treatment with low doses of aspirin promoted a discrete inhibitory effect in the early stages (7 days) of repair after implant placement, specifically in the bone deposition. However, these effects were not detected in the late stages (28 days), considering BIC and BABT parameters.
Highlights
Dental implants have been considered as a safe and predictable strategy of rehabilitation for partially or completely edentulous patients with high success rates [1, 2]
After 7 days, a significant reduction in bone-to-implant contact (BIC) values was detected in the presence of a low-dose aspirin (AG-7 group), compared to the control group (CG-7 group) (p < 0.05, Figs. 1 and 3)
This reduction in BIC results was not detected between Control groups (CG) and AG groups after 28 days (p > 0.05, as illustrated in Figs. 1 and 3)
Summary
Dental implants have been considered as a safe and predictable strategy of rehabilitation for partially or completely edentulous patients with high success rates [1, 2] These elevated success rates are essentially associated with osseointegration, which is defined as a requisite for the long-term success of implant-supported prostheses. Several drugs are capable of promoting changes in bone metabolism [6] In this context, the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) is Aspirin, called acetylsalicylic acid, is known as a group of drugs that belongs to NSAIDs and inhibits cyclooxygenase-1 (COX-1) and COX-2 enzymes. In the 1980s, the FDA approved the use of aspirin in low doses for the prevention of cardiovascular diseases This clinical indication is related to the inhibition of platelet aggregation decurrent of the reduction. Histomorphometric evaluation of bone-to-implant contact (BIC) and the bone area between threads (BABT) was performed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
